| |
Tech ID |
Status of IP |
Technology |
Utility |
| |
2002-001-001 |
US and foreign patent applications pending |
3D imaging of large number of thick 2D specimens in short time ("Genome-Scale Imaging") |
Confocal Microscopy |
| |
2006-004-001 |
US provisional patent application |
Magnetic resonance spectroscopy |
As a cancer diagnostic |
| |
Tech ID |
Status of IP |
Technology |
Utility |
| |
2000-002-001 |
US patent coverage until 2021. Foreign patents & patent
applications pending |
Assay for rapid detection of Activated Protein C in blood using a monoclonal antibody |
In Thrombosis & Sepsis |
| |
SA 06100 |
US patent coverage until 2103. Foreign patents & patent
applications pending |
Assay for selective Protein C inhibition (by auto-antibody) |
In Thrombosis & Sepsis (improved clotting assay) |
| |
SA 06700 |
US patent coverage until 2014 |
Method of detecting antibodies to thrombomodulin in patients |
In Thrombosis & Sepsis. Assay identifies people whose blood have
auto-antibodies to thrombomodulin |
| |
2003-004-004 |
US patent application published |
Predicting susceptibility to cardiovascular disease by measuring s-EPCR |
In Thrombosis & Sepsis |
| |
2001-004-001 |
US and foreign patent applications |
Assay to monitor thrombin production |
In Thrombosis & Sepsis |
| |
SA 10900 |
US patent coverage until 2021. Foreign patents & patent
applications pending |
Thrombotic episode risk assays (improved clotting assays) |
Detects presence of auto-antigens indicative of risk for venous
& arterial thrombosis |
| |
Tech ID |
Status of IP |
Technology |
Utility |
| |
OMRF 120 |
US patent coverage until 2020 |
Protein antigen to screen for Polymyositis and Dermatomyositis |
Diagnostic for muscular degeneration disease |
| |
OMRF 138 |
Issued US and foreign patents. US patent coverage until 2015 |
Peptide based technology to screen for reactive T cells indicative of
spondyloathropathies |
Diagnosis and treatment of spondyloarthtopathies (like Ankylosing
Spondylitis, Reiter's syndrome, & arthritic disorders that involve spinal inflammation) |
| |
Tech ID |
Status of IP |
Technology |
Utility |
| |
OMRF 165 |
US patent coverage until 2016. |
Modified Protein - C & its use |
Highly effective anticoagulant in the treatment of Thrombosis |
| |
OMRF 167 |
US patent coverage until 2016. Foreign patent applications pending |
Modified Protein - C & its use |
Treatment of Factor V Leiden patients susceptible to Thrombosis |
| |
OMRF 152 |
US patent coverage until 2014. Foreign patents & patent
applications pending |
Therapeutic uses of anti-human endothelial Protein C receptor (EPCR) |
Evolving technology on function of EPCR in cardiovascular diseases |
| |
2001-002-002
(Jointly owned with
McMaster University
of Canada) |
US patent coverage until 2022. Foreign patent applications pending |
Treatment of sepsis with thrombin-activatable fibrinolysis inhibitor (TAFI) |
Sepsis Treatment |
| |
2006-002-001 |
US Provisional patent application |
Treatment for ulcerative colitis (mucin
therapy) |
Potentially a food supplement product |
| |
1998-010-001 |
Several US patents issued. Additional US and foreign patent applications
pending |
Use of melanocyte stimulating hormone (MSH) agonists and antagonists |
Treatment of Obesity and Diabetes |
| |
Tech ID |
Status of IP |
Technology |
Utility |
| |
2003-005-003 |
US and foreign patent applications pending |
Inhibition of Bright transcription
factor against autoimmune diseases |
Treatment of Lupus & other autoimmune diseases |
| |
OMRF 176 |
US patent coverage until 2020. Foreign patent applications pending |
Protease inhibitors that overcome drug
resistance |
Treatment of pathogens, especially in the case of HIV |
| |
2004-005-001 |
US and foreign patent applications pending |
Mini-immunoglobulin expression cassettes under TATA promoter control |
Treatment of immunity related deficiencies |
| |
2005-005-002 |
US patent application / PCT |
Replenishment of innate immune system by regulating
Toll-like Receptors (TLRs) on Hematopoetic Stem Cells |
Treatment of inflammatory / infectious diseases and treatment of immunity related
deficiencies |
| |
Tech ID |
Status of IP |
Technology |
Utility |
| |
2002-004-001 |
US and foreign patent applications pending |
Compounds (Tethered Dicathechols) to treat neuro-inflammation |
Treatment of neurodegenerative / CNS diseases |
| |
2005-004-004 |
US provisional patent application |
Lanthionine related compounds for treatment of neuro-inflammation |
Treatment of neurodegenerative / CNS diseases |
| |
Tech ID |
Status of IP |
Technology |
Utility |
| |
2006-003-001 |
Provisional Patent Application |
Protein-engineering approach to making soluble proteins to G Protein
Coupled Receptors (GPCR) |
X-ray crystallography tool, which would allow solution of crystal
structure for large family of molecules important as drug targets. (Early state technology) |
| |
OMRF 118 |
US patent coverage until 2017 |
Nucleic acid for Ro52 autoantigen |
In Lupus research |
| |
OMRF 152 |
US patent coverage until 2018 |
h-EPCR reagents (nucleic acid, proteins, antibodies) |
Research tools in identifying stem cells. Also, as a reagents in
diagnostic assays measuring EPCR |
| |
SA 06500 |
US patent coverage until 2015 |
RNA polymerase II transcription factor. (Enzyme significantly
increases rate of transcription elongation by RNA polymerase II) |
Transcription research & genetic engineering |
| |
SA07500 |
US patent coverage until 2016 |
Elongin A and C functional domain polypeptides |
Transcription research & genetic engineering |
| |
2001-007-001 |
A US patent issued. Additional US and foreign patent applications pending |
Construction and characterization of GFP-fusion proteins targeted to
discrete compartments of plasma membrane |
Signal transduction biology |
Email this page
